<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336346</url>
  </required_header>
  <id_info>
    <org_study_id>AAAQ8556</org_study_id>
    <nct_id>NCT03336346</nct_id>
  </id_info>
  <brief_title>Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana</brief_title>
  <official_title>The Effect of Dolutegravir-based ART on Plasma Etonogestrel Levels in HIV-infected Women Using Contraceptive Implants in Botswana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim is to assess if etonogestrel (ENG) implant users taking dolutegravir (DTG)
      have a 20% or greater change in their ENG plasma levels, compared to women taking no
      antiretroviral therapy (ART). A secondary aim is to assess whether ENG implant users taking
      dolutegravir have significantly higher ENG plasma levels than ENG implant users taking
      efavirenz.

      This is a cross-sectional, non-randomized evaluation to compare ENG levels at least 3 months
      post-implant insertion in three groups of women: 1) women using DTG-based ART (n=90), 2)
      women using EFV-based ART (n=90), and 3) women using no ART (not HIV infected) (n=90). This
      study will be conducted in Botswana in Southern Africa among women using the ENG implant, and
      involves a one-time collection of blood and questionnaire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efavirenz-based antiretroviral therapy is effective in treating HIV and had become standard
      in the World Health Organization (WHO) guidelines. However, despite its effectiveness in
      lowering viral load, there is also solid evidence that it decreases the effectiveness of
      etonogestrel-releasing implants. This presents a difficult clinical scenario in countries
      where the HIV burden is significant in reproductive age women.

      Following the SINGLE trial, dolutegravir has replaced efavirenz in many settings as
      first-line ART. In 2016, Botswana became the first country in Africa to adopt this as a
      guideline, however, the effect that dolutegravir has on hormonal contraceptives has not been
      widely studied. This project seeks to understand the interaction between etonogestrel levels
      in HIV-infected women who are using dolutegravir-based ART by directly measuring etonogestrel
      blood levels using liquid chromatography-mass spectrometry in HIV-negative and HIV-infected
      women using contraceptive implants.

      Because the implant is fairly new in Botswana, most participants will have had implants
      inserted 3-12 months prior to study. An HIV-infected, non-ART, comparison group is no longer
      permissible, practically or ethically, as countries across Africa, including Botswana, are
      moving to HIV &quot;Test and Treat.&quot; This means that ART initiation is now occurring at time of
      HIV-diagnosis regardless of cluster of differentiation 4 (CD4) count or disease stage;
      therefore, in this study, the comparison group will be HIV-uninfected implant users. This
      comparison will answer the key question of whether the ENG implant when used simultaneously
      with DTG provides plasma ENG levels comparable to a group in which it has established
      contraceptive efficacy (i.e. HIV-uninfected, healthy women of reproductive age).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference (percentage) in ENG plasma levels in the DTG group compared to no ART group</measure>
    <time_frame>Up to 12 months after implant</time_frame>
    <description>Difference between the DTG group and no ART group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference (percentage) in ENG plasma levels in the DTG group compared to EFV group</measure>
    <time_frame>Up to 12 months after implant</time_frame>
    <description>Difference between the DTG group and EFV group</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Contraceptive Usage</condition>
  <condition>HIV Infections</condition>
  <condition>Drug Interaction</condition>
  <arm_group>
    <arm_group_label>DTG group</arm_group_label>
    <description>Reproductive-aged HIV-infected women taking dolutegravir-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No ART group</arm_group_label>
    <description>Reproductive-aged HIV-uninfected women using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EFV group</arm_group_label>
    <description>Reproductive-aged HIV-infected women taking efavirenz-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dolutegravir</intervention_name>
    <description>HIV integrase strand transfer inhibitor used in combination ART</description>
    <arm_group_label>DTG group</arm_group_label>
    <other_name>Tivicay</other_name>
    <other_name>DTG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ENG implant</intervention_name>
    <description>Reversible contraception implant</description>
    <arm_group_label>DTG group</arm_group_label>
    <arm_group_label>No ART group</arm_group_label>
    <arm_group_label>EFV group</arm_group_label>
    <other_name>Nexplanon ®</other_name>
    <other_name>Implanon NXT ®</other_name>
    <other_name>single-rod, etonogestrel-releasing, subdermal implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>non-nucleoside reverse transcriptase inhibitor used in combination ART</description>
    <arm_group_label>EFV group</arm_group_label>
    <other_name>Sustiva</other_name>
    <other_name>EFV</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Reproductive-aged HIV-infected women using dolutegravir and using single-rod,
        etonogestrel-releasing subdermal implant.

        Reproductive-aged HIV-infected women using efavirenz and using single-rod,
        etonogestrel-releasing subdermal implant.

        Reproductive-aged HIV-unifected women using single-rod, etonogestrel-releasing subdermal
        implant.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Etonogestrel implant as their sole method of hormonal contraception

          -  Etonogestrel implant in-situ for at least 3 months

          -  Dolutegravir (DTG) use for at least 60 days (Using DTG-based ART-regimen if
             applicable)

          -  Efavirenz (EFV) use for at least 60 days (Using EFV-based ART-regimen if applicable)

        Exclusion Criteria:

          -  Exclude women using concomitant enzyme-inducing drugs, including rifampicin for
             tuberculosis treatment and anti-convulsant medications (phenytoin, carbamazepine,
             barbiturates, primidone, topiramate, oxcarbazepine)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn L Westhoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolyn L Westhoff, MD</last_name>
    <phone>212-305-4805</phone>
    <email>clw3@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ian Bishop, MD</last_name>
    <phone>212-305-4938</phone>
    <email>ib2389@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Botswana-UPenn Partnership</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea Morroni, MD</last_name>
      <phone>26776524112</phone>
      <email>chelseaamorroni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chelsea Morroni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Botswana</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Carolyn L. Westhoff</investigator_full_name>
    <investigator_title>Professor of Population and Family Health; Chief, Division of Family Planning &amp; Preventive Services</investigator_title>
  </responsible_party>
  <keyword>DTG</keyword>
  <keyword>Dolutegravir</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>Etonogestrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

